Interested in Participating in a Clinical Study?
Clinical Research – Cardiovascular Studies
If you are interested in participating, connect with your cardiovascular specialist.
For the past 15 years, cardiovascular clinicians have been conducting research at Cottage. More than 30 unique clinical trials have brought innovative technology, life-saving devices and expanded medication choice to Cottage patients that wouldn’t otherwise be available. The treatment options from these clinical trials will continue to enhance existing medical services provided to patients by Cottage clinician researchers.
Cardiovascular research at Cottage Health covers a spectrum of investigation and encompasses the different areas of cardiovascular expertise of our health care providers. Our research extends to investigational clinical trials (phases III-IV), registries, and retrospective studies. CH conducts industry-sponsored trials as well as investigator-initiated studies.
The Cottage Health Research Institute (CHRI) is an integral part of Cottage Health. For more than 20 years, CHRI has offered consultation, liaison, and administrative resources to researchers to support the translation of clinical and academic research. CHRI works closely with investigators to implement protocols at Cottage Health and assists in participant screening, consenting, enrolling, conducting study visits, and collection and entry of data.
Participation in clinical trials allows Cottage Health to offer the best possible range of treatment options and access to cutting-edge treatments for patients in our own community.
Current Open to Enrollment Cardiovascular Clinical Trials
Study Sponsor: W.L. Gore & Associates, Inc.
Principal Investigator(s): Aragon (PI), Shenoda, Delio
The REDUCE PAS study is a post approval study assessing the safety and effectiveness of the GORE Septal Occluder device as observed in the REDUCE pivotal IDE study, and evaluating the quality of operator education and training and transferability of trial experience to a post-market setting.
The full study title is “GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO): the REDUCE Post Approval Study”.
TARGET-IV NA Trial
Study Sponsor: Cleveland Clinic
Principal Investigator(s): Aragon (PI), Kumar, Shenoda
The TARGET-IV NA study is a prospective clinical trial for patients undergoing percutaneous coronary intervention. This study will compare the efficacy and safety of the Firehawk™ rapamycin target eluting cobalt chromium coronary stent system to FDA approved drug eluting stent (DES) systems.
Study Sponsor: Boston Scientific
Principal Investigator(s): Aragon (PI), Cogert, Shenoda, Shafer
CHAMPION-AF is a prospective, randomized, multi-center global investigation. The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
The START Study
Study Sponsor: Renibus Therapeutics, Inc
Principal Investigator(s): Tedesco (PI), Baay
The START study is a phase 2, double-blind, randomized, placebo-controlled investigation. The purpose of this study is to evaluate the effect of RBT-1 (stannous protoporphyrin [SnPP]/iron sucrose [FeS]) on preconditioning response biomarkers in subjects who are at risk for AKI following cardiac surgery.
Nationally Recognized Research
TCT Conference in San Francisco
Dr. Joseph Aragon and the Cottage Structural Heart team presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
The Transcatheter Cardiovascular Therapeutics conference is one of the world’s largest and most influential educational meetings specializing in interventional cardiovascular medicine.